With the rapid development and complex challenges of chemical substances, new drug synthesis pathways are usually the most effective.137076-54-1,2-(4,7,10-Tris(2-(tert-butoxy)-2-oxoethyl)-1,4,7,10-tetraazacyclododecan-1-yl)acetic acid,as a common compound, the synthetic route is as follows.
To a solution of 2 (194 mg, 0.09 mmol) and 3 ( 52mg, 0.09ml) in acetonitrile (8ml), HTBU ( 34mg, 0.09 mmol) wa added followed by triethylamine ( 25 muL, 0.18mmol) at RT. the reaction was stirred for 18 h. The reaction was diluted with 30 mL dichloromethane and washed 0.1 N HCl(30 mL), 10% NaHCO3 (30 mL), brine (30 mL), then dried over MgSO4, and concentrated. The crudeproduct was purified by column chromatography (DCM:MeOH = 97:5 DCM:MeOH = 85:15) togive 4 (Figure 7) as a foam (105 mg, 43%). 1H-NMR (400 MHz, CDCl3): delta 3.68-3.47 (m, 104H,CH2OCH2CH2OCH2CH2OCH2, C3N3-NHCH2CH2CH2O , Dota-CONHCH2CH2CH2O), 3.22-3.18(br m, 8H, BocNHCH2), 1.84-1.72 (m, 28H, OCH2CH2CH2), 1.46 (s, 9H), 1.45 (s, 9H), 1.42 (s, 45H);13C-NMR (100 MHz, CDCl3) delta 176.6 (DOTA-OCOtBu), 174.4 (DOTA-OCOtBu), 172.3 (DOTA-OCOtBu),not found (C3N3), 156.0 (NHCOtBu), 81.7 (DOTA-OC(CH3)3), 78.7 (C(CH3)3), 70.47 (OCH2CH2O),70.21 (OCH2CH2O), 70.17 (OCH2CH2O), 70.10 (OCH2CH2O), 69.42 (CH2CH2CH2O), 69.02(CH2CH2CH2O), 57.5 (DOTA), 56.2 (DOTA), 55.6 (DOTA), 53.5 (DOTA), 41.9 (NH2CH2CH2CH2O),38.5 (CH2CH2CH2O), 38.4 (CH2CH2CH2O), 29.6 (NH2CH2CH2CH2O), 29.3 (NH2CH2CH2CH2O),28.4 (C(CH3)3), 27.94 (DOTA-OC(CH3)3), 27.87 (DOTA-OC(CH3)3); MS (ESI-TOF) calcd. forC127H242N27O36 2721.7936, found 2721.8117 [M + H]+. Spectra appear in the Supplementary Materials:Figures S11-S13
137076-54-1, As the paragraph descriping shows that 137076-54-1 is playing an increasingly important role.
Reference£º
Article; Lee, Changsuk; Ji, Kun; Simanek, Eric E.; Molecules; vol. 21; 3; (2016);,
Metal catalyst and ligand design
Ligand Template Strategies for Catalyst Encapsulation – NCBI